Bruker (NASDAQ:BRKR) is seeing stronger order momentum across several end markets, with semiconductor metrology, non-U.S. academic and government customers, and parts of its diagnostics business helping offset continued weakness in U.S. academic funding, a company representative said at a Jefferies healthcare conference.
In a discussion hosted by Jefferies analyst Tycho Peterson, Gerald, speaking for Bruker, said the highlight of the company’s first quarter was order performance. He said Bruker had “good, strong order performance” in the quarter following a solid fourth quarter, and indicated the company appears on track for three consecutive quarters with a book-to-bill ratio above 1.0.
